Updated global consensus guidelines for cold agglutinin disease (CAD), alongside post-hoc Phase 3 analysis and real-world data, supplement evidence of sutimlimab long-term safety and efficacy in CAD Research findings and the first globally validated symptom burden tool for idiopathic...
Hence then, the article about recordati and partners to present new evidence and guidance in rare hematologic diseases at american society of hematology ash annual meeting and exposition was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Recordati and Partners to Present New Evidence and Guidance in Rare Hematologic Diseases at American Society of Hematology (ASH) Annual Meeting and Exposition )
Also on site :